Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407897 | 0.92 | ALDH1A1 (0.36) | KIF11POLBNOS3NOS2ALDH1A1 | |
| SCHEMBL2050325 | 0.77 | KIF11 (0.40) | KIF11POLBNOS3NOS2ALDH1A1 | |
| SCHEMBL2052473 | 0.77 | NOS3 (0.32) | NOS3NOS2ALDH1A1TSHRNOS1 | |
| SCHEMBL27766777 | 0.76 | KIF11 (0.37) | KIF11POLBNOS3NOS2ALDH1A1 | |
| SCHEMBL29539147 | 0.72 | KIF11 (0.42) | KIF11POLBNOS3NOS2ALDH1A1 | |
| SCHEMBL497630 | 0.68 | TSHR (0.38) | POLBNOS3NOS2ALDH1A1TSHR | |
| SCHEMBL577126 | 0.68 | — | — | |
| SCHEMBL29285276 | 0.68 | DRD3 (0.36) | KIF11NOS3NOS2ALDH1A1TSHR | |
| SCHEMBL27858991 | 0.68 | PIK3C3 (0.32) | KIF11NOS3NOS2ALDH1A1TSHR | |
| SCHEMBL12482758 | 0.68 | MAPK1 (0.36) | KIF11NOS3NOS2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1272488-B1 | TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2006-03-22 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-6841564-B2 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-01-11 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-6639077-B2 | Ethanes substituted with a phenyl, a thiazole, and a pyridyl are phosphodiesterase (PDE4) inhibitors; leukotriene receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2003-10-28 | — | — | US | disclosed |
| EP-1272488-A2 | TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | disclosed |
| US-20020173661-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA & CO. | 2002-11-21 | — | — | US | disclosed |
| US-20020156105-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-6399636-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), EOSINOPHILIC GRANULOMA, PSORIASIS AND SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN | MERCK FROSST CANADA & CO. (CA) | 2002-06-04 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-20020013347-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| WO-2001070738-A2 | TRI-ARYL-SUBSTITUTED-ETHANE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173661-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | KIF11 2245/4885POLB 2383/4885NOS3 589/4885 |
| US-20020156105-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | KIF11 2245/4885POLB 2383/4885NOS3 589/4885 |
| US-20020013347-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | KIF11 2813/4885POLB 2694/4885NOS3 646/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | KIF11 237/4885POLB 3161/4885NOS3 1890/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | KIF11 703/4885POLB 3192/4885NOS3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.